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The Joint Accreditation Committee of ISCT-EBMT ( JACIE) is a non-profit body first established in 1998 for the assessment and ac-
creditation of hematopoietic stem cell (HSC) transplan-
tation programs.1 The Committee was founded by the 
European Group for Blood and Marrow Transplantation 
(EBMT) and the International Society for Cellular 
Therapy (ISCT), the two leading scientific organiza-
tions involved with HSC transplantation in Europe. 
JACIE modelled itself on the US-based Foundation for 
the Accreditation of Cellular Therapy (FACT), estab-
lished in 1996 by the ISCT and the American Society 
for Blood and Marrow Transplantation (ASBMT).2 
JACIE works closely with FACT through a joint com-
mittee structure to establish standards for the provi-
sion of quality medical and laboratory practice in HSC 
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Jacie was initiated as a small pilot project in spain in 2000 and launched as a formal europe-wide 
inspection program in January 2004. since 2000, over 150 applications for accreditation have been 
received by the Jacie office and more than 130 inspections have been completed in european cen-
ters and facilities. almost all of these were found to be functioning at a high level of excellence, with 
the majority having only minor deficiencies in compliance with the standards. in one-third of centers 
there were more significant deficiencies. the most common deficiencies were in quality management. 
following correction of deficiencies 86 centers have to date achieved full accreditation and many more 
are nearing the completion of the process. implementation of Jacie involves a significant investment 
of time and resources by applicant centers. the majority require at least 18 months to prepare for ac-
creditation and 85% have needed to employ a quality manager and/or data manager on an ongoing 
basis. however, all centers felt their program had benefited from the implementation of Jacie. Jacie 
is also working closely with other international organisations related to cellular therapy as part of the 
alliance for the harmonisation of cell therapy accreditation (ahcta), which is examining the differ-
ences in existing standards and aiming to develop international standards for all aspects of stem cell 
transplantation. in particular the requirements for safety of imported tissues and cells has emphasised the 
need for global harmonisation. the recent implementation of directive 2004/23/ec and the associated 
commission directives 2006/17/ec and 2006/86/ec has provided an impetus for the implementation of 
Jacie in european union (eu) member states. it will be important in the future to examine how Jacie 
can co-operate with the eu competent authorities (ca) to ease the burden of the inspection process for 
haemopoietic stem cell (hsc) transplant programs. 
transplantation. JACIE conducts inspections, accredits 
transplant programs and encourages health institutions 
and facilities performing HSC transplantation to vol-
untarily meet these standards to demonstrate their high 
levels of quality of care. 
The primary aim of JACIE is to improve the qual-
ity of HSC transplantation in Europe by providing a 
means whereby clinical transplant centers, HSC collec-
tion facilities and processing facilities can demonstrate 
excellence. This is supported by its co-ordinating role in 
the provision of training courses in quality management 
for applicant centers and training courses for inspectors. 
An additional and wider aim is to ensure harmonisation 
between JACIE standards and other national/inter-
national standards, including the EU Tissues & Cells 
Directive 2004/23/EC3 and the related implement-
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Figure 1. initial applications to jaCie by country between 2000-2008.
ing directives 2006/17/EC4 and 2006/86/EC.5 The 
increasing use of unrelated donor cells for transplants 
highlights the need for further work in this area. 
HSC transplant programs become accredited follow-
ing on-line submission of documentation and an on-site 
visit by a team of trained inspectors. Centers may apply 
for accreditation as complete programs comprising a 
clinical program, a collection facility and a processing 
laboratory or, for example, as a single collection or pro-
cessing facility serving one or more clinical programs. 
JACIE accreditation is voluntary, but provides a means 
whereby transplant facilities can demonstrate that they 
are working within a quality system covering all aspects 
of the transplantation process and thus show compli-
ance with the requirements of insurance companies or 
national and/or international regulatory authorities. 
The JACIE program was run as a pilot program in 
Spain between 2000 and 2002 and formally launched 
on an international basis in January 2004 with sup-
port from the European Union under the Public 
Health Program (2003-2008) (http://ec.europa.eu/
health/ph_projects/2003/action2/action2_2003_05_
en.htm). Between January 2000 and November 2008, 
139 centers or facilities have been inspected for the 
first time and 16 have been re-inspected. The number 
of applications/inspections per country is Austria 2/3, 
Belgium 8/3, Czech Republic 3/1, Finland 3/3, France 
22/20, Germany 27/20, Italy 17/11, The Netherlands 
20/16, Poland 1/0, Saudi Arabia 1/1, Spain 10/7, 
Switzerland 10/16, Turkey 1/1, and the United 
Kingdom 33/37 (Figure 1 shows initial applications by 
country). This experience has enabled JACIE to iden-
tify areas of common difficulty for applicant centers, to 
assess what assistance centers need in order to achieve 
accreditation, and has also raised some general issues 
relating to national and international regulation. 
The FACT-JACIE Standards
The 4th edition of the joint FACT-JACIE standards 
covers all aspects of clinical transplant programs, collec-
tion facilities (bone marrow [BM] and peripheral blood 
progenitor cell [PBPC] collection) and processing of 
HPC, as shown in Table 1. These superseded the 3rd 
edition at the start of November 2008. The 4th edition 
will be the standard against which programs are inspect-
ed from 1st February 2009.6 The updated standards 
are applicable to cellular therapy products (CTP) but 
where applicable only to hemopoietic progenitor cells 
(HPC), this is specifically referenced. The standards 
also apply to the use of therapeutic cells (TC) derived 
from blood or marrow, including donor lymphocytes. 
Important changes in the 4th edition are as follows:
1.  Quality Management (QM): the standards have 
been realigned to reduce redundant references to 
QM topics and have been organized in each sec-
tion on a topical basis. Standards pertaining to 
operational quality control have been relocated to 
the relevant operational sections
2.  Standard Operating Procedure (SOP) review: 
the requirement has been changed from annual to 
biannual (or upon the introduction of changes in 
procedures, whichever is sooner).
Figure 2. extract from the inspection checklist. Both applicants and inspectors complete 
all sections of this document. individual responses are then automatically coded green 
(‘yes’ response), blue (‘non-applicable’ response) and red (‘no’ response). Blue and red 
responses prompt the addition of additional information/explanation
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3.  The donor selection, evaluation, and management 
sections in the clinical program and collection fa-
cility sections have been modified to reflect the 
way that these responsibilities are divided between 
clinical programs and collection facilities. The col-
lection facility standards focus more on donor 
evaluation and management, with less emphasis 
on donor selection activities. In some situations 
the collection facility is primarily responsible for 
donor selection activities, and the standards now 
state that in these situations, collection facilities 
are required to comply with the applicable clinical 
program standards. 
4.  Early discharge from the transplant center. It 
was agreed by the FACT-JACIE Standards 
Committee that it is against the spirit of the stan-
dards to inspect and accredit the center perform-
ing the transplant procedure as the “transplant 
center” without considering post-transplant care. 
With this in mind the 4th edition of the standards 
states that Clinical Programs shall ensure planned 
discharges are to facilities adequate for post-trans-
plant care. This means that it is the responsibility 
of the transplant center to ensure compliance with 
items such as the provision of isolation facilities, 
staffing and training and policies and procedures. 
JACIE will require documentation of compliance 
and this might in the future include inspection of 
the hospital providing post-transplant care.
5.  Appendices have been revised to clarify require-
ments and simplify the standards. Those that 
are external tables and forms have been removed 
and replaced with a reference table indicating the 
websites where the current versions can be found. 
This is in response to situations in which exter-
nal tables and forms are updated within months 
of publication of FACT-JACIE standards, which 
causes the appendices to become out of date be-
Table 1. analysis of Most Common Deficiencies
Clinical program Collection facility Processing facility
Donors QM plan QM plan
•  Missing or inconsistent donor 
information e.g. vaccinations, travel, 
pregnancies and blood transfusion 
histories
•  Lack of written information e.g. on 
collection procedures
• No QM plan
•  Present but with significant omissions 
e.g. lack of validation procedures 
•  Lack of integration with the facilities 
activities
• No validation or qualification studies
• System for audits inadequate
*iDMs Policies and procedures Policies and procedures
•  Medical history doesn’t include the 
correct questions
• Specific tests omitted
•  Tests not done within 30 days of HPC 
transplant
• Present but inadequate
•  No range of expected outcomes/
results
• No procedures for recording deviation
• No reference section
• Present but inadequate
•  No range of expected outcomes/
results
• No procedures for recording deviations
• No reference section
Data management Review of new/revised documents Process control
• incomplete or incorrect forms
• Lack of engraftment data
•  Clinical status at HPC transplant not 
recorded
• Chemo: lack of prescription
•  Failure to undertake or document 
review
• No written request for processing
• No review of processing records
• aBO, Rh tests not done
adverse events, errors and clinical 
incidents Collection procedures Labelling
• Not reported or recorded
• Lack of regular audit
• No corrective actions
• insufficient number of BM procedures
• Lack of written order for collection
• No interim donor checks
• incorrect product name used
•  information missing from labels e.g. 
date/time allocated, volume etc.
• No unique alphanumeric identifier
Outpatient facilities engraftment data engraftment data
• Lack of space
•  inadequate separation of patients with 
significant infections
• Failure to document and review time to 
engraftment
• Failure to document and review time to 
engraftment
*iDMs – infectious disease markers e.g. HiV – 1/2
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Figure 3. Cumulative numbers of initial applications and total inspections between 2000-
2008.
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Figure 4. initial applications for inspection by year between 2000-2008.
fore the next edition is published. 
6.  Expanded requirements: an effort has been made 
to simplify the standards since they are intended 
to define minimum standards rather than best 
practice. Some requirements have been expanded 
and specific examples include:
 • Written agreements – the responsibility of en-
suring external entities comply with Standards 
and governmental laws and regulations is 
placed on the clinical program/collection facil-
ity/processing facility as appropriate.
•  Disaster plans – explicitly states in standard 
the requirement to include the response of 
the clinical program/collection facility/pro-
cessing facility as appropriate.
•  Concurrent plasma and samples are required 
to have the same identifier as the cellular 
therapy product.
7.  Terminology: in several cases the use of specific 
terminology was clarified to reduce misinterpreta-
tions commonly found during the inspection and 
accreditation process and also to account for in-
ternational variations. Specific examples include:
•  Change from HPC to CTP where applica-
ble. In instances where only HPC applies it is 
specifically referenced.
•  Board eligibility/certification references 
changed to ‘specialist certification’ to accom-
modate international education.
•  References to specific governmental agencies 
and accrediting bodies, e.g. the United States 
Food and Drug Administration (FDA) etc 
have been changed to ‘appropriate govern-
mental authorities’ or ‘certified as required by 
governmental authorities’ as appropriate.
•  Validation has been redefined to include 
only processes (including intended uses of 
equipment) and qualification to include only 
equipment, supplies, and reagents (in align-
ment with FDA interpretation).
There are also a number of specific sectional changes 
which are not described here
The complete standards and the accompanying 
guidance manual are available on the FACT and JACIE 
websites.  They are broadly consistent with the require-
ments of the Tissues and Cells Directive (2004/23/EC) 
and accompanying Commission Directives (see above) 
as regards donation, procurement and processing of 
stem cells, but in addition, cover the clinical transplant 
program. Accreditation of clinical programs includes 
the clinical use of cord blood (CB) stem cells but the 
JACIE program does not accredit CB collection and 
banking facilities as this process is currently carried out 
by FACT against the Netcord-FACT Standards.7
The FACT-JACIE Manual and Inspection 
Checklist
The manual contains the standards together with de-
tailed guidance on the interpretation and measures re-
quired to demonstrate compliance. Each standard is fol-
lowed by specific questions relating to that standard and 
these questions form the basis of the inspection check-
list, which must be completed prior to inspection by the 
applicant center and verified by the inspector during the 
special communicationjaCie
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Figure 5. Provisional data showing the proportion of centers 
reporting transplants to the 2007 eBMT activity Survey that have 
applied for jaCie accreditation and meet the minimum transplant 
requirements.
inspection. The checklist has recently changed format 
from Microsoft Word to Microsoft Excel to facilitate 
the completion of the checklist by both the applicant 
and the inspector and to make analysis of the answers 
easier by using automatic colour-coding and including 
filters (Figure 2).
The Accreditation Process
Preparation by Center
The center implements measures as described in the 
FACT-JACIE accreditation manual, and then applies 
for inspection by submitting basic information about 
the program/facility and a number of supporting docu-
ments including a self-assessment checklist. The appli-
cation information and checklist must be submitted in 
English but all other documentation, including SOPs is 
accepted in the language of the center.
Inspection 
An on-site visit is carried out by a team of trained in-
spectors, usually one per facility (clinical / collection / 
processing). Inspectors are medical, scientific or other 
professional persons working in HSC transplantation, 
with specific qualifications and experience for inspecting 
clinical, collection and/or processing facilities. Inspectors 
must attend a JACIE-sponsored training course and 
pass an examination. Where a clinical program performs 
adult and paediatric transplants, an adult and a paediatric 
inspector will attend. Inspectors may also be from anoth-
er country but should be either native or fluent speakers 
of the relevant language. An inspection visit usually lasts 
1.5 days and involves discussion with staff during their 
work, review of documents /records and completion of a 
detailed checklist relating to the standards. 
The report is prepared in English, notes any areas 
of non-compliance with the standards and is reviewed 
by the JACIE Office and Accreditation Committee, 
the latter established in 2006. This report indicates all 
non-compliances with specific standards and makes 
specific recommendations for corrections and improve-
ments. The distinction between minor deficiencies and 
more significant deficiencies is not strictly defined, but 
in general terms, specific deficiencies in documentation 
are considered minor while more general problems with 
documentation or problems with processes or facilities 
are considered significant. The center is allowed up 
to 9 months to correct deficiencies, depending on the 
amount of work required. 
Center Response 
The center must indicate acceptance of the findings 
and then in due course submit documentary evidence 
to confirm corrections or amendments. The original 
inspectors review the documentation. Review by the in-
spectors rather than by the Accreditation Committee is 
required because of language issues. In some cases a full 
or limited re-inspection may be required to show that 
deficiencies have been corrected. The inspectors con-
firm to the JACIE Office that all necessary corrections 
have been made or indicate that there are still outstand-
ing areas for completion.
Accreditation 
The JACIE Office and Accreditation Committee re-
views all the reports and relevant documentation and if 
satisfied that all deficiencies have been corrected, make 
a recommendation to the JACIE Board that the center 
be awarded accreditation. If approved, accreditation is 
awarded, valid for 4 years, subject to an annual report 
from the center noting any significant changes in person-
nel or procedures and including annual activity figures 
and an interim audit at the end of the second year of 
accreditation.
Summary of JACIE Inspection Activity
To date, 156 facilities have formally applied for accredi-
tation. Ninety-nine centers applied for accreditation for 
a combination of clinical, collection and processing fa-
cilities; 20 centers applied for clinical only; 1 for bone 
marrow harvest only; 12 centers applied for clinical and 
collection only; 4 for apheresis collection only; 8 centers 
applied for collection and processing only; and 12 for 
processing only. Between January 2000 and November 
2008 139 centers were inspected (Figure 3) including 
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Figure 6. Deficiencies categorized from 1732 inspections carried out between 2004 
and 2007. Problems with the quality management program, SOPs, labelling, and donor 
assessment/management are found most frequently.
both first-time and reaccreditation inspections. The 
number of first-time or initial applications rose to 33 in 
2007 and 31 applications have been received to date in 
2008 (Figure 4) although the overall number of applica-
tions is higher as a result of requests for reaccreditation. 
Figure 5 shows the overall proportion of transplant 
centers reporting to the EBMT that are now JACIE 
registered. 
Common Deficiencies 
The most common deficiencies were in documentation, 
labelling and in the quality management program. This 
is consistent with the initial experience of the FACT 
accreditation program in the United States and is de-
scribed in more detail in the next section. Minor fail-
ures of compliance were frequent, usually involving 
problems with documentation. Examples include:
• SOPs not containing key references
•  Pregnancy assessment not documented during do-
nor evaluation 
More significant failures of compliance were less 
common. Examples include:
•  Program not functioning as a single program (e.g. 
SOPs not uniform across different clinical sites, for 
example where allogeneic and autologous patients, 
or adult and paediatric patients were treated on dif-
ferent sites)
•  Outpatient facilities inadequate (e.g. no provision 
for isolation of infectious patients)
• Inadequate quality management program 
•  No continuous temperature monitoring of freezers 
in processing facility
•  Temperature not monitored during transport of 
HSC from processing facility to clinical unit 
•  Engraftment data not monitored by processing fa-
cility
Some of these significant deficiencies arose from 
lack of resources, e.g. size of laboratory inadequate for 
workload or lack of an experienced quality manager. 
Analysis of Deficiencies 
Deficiencies in the quality management program were 
by far the most common cause of failure of compliance 
with the standards and, including problems with poli-
cies and procedures (SOPs), accounted for 37% (636 of 
1732) of total cited deficiencies (Figure 6). Deficiencies 
included: 
•  Problems with the formatting and content of 
SOPs, example:
–  missing examples of worksheets/forms/la-
bels
– missing references (where relevant)
–  failure to include range of expected results 
(where relevant)
•  Lack of procedure for documenting deviations 
from SOPs 
• Lack of regular review process for SOPs 
•  No SOPs for critical procedures e.g. bone marrow 
collection 
• Inadequate document control procedure 
•  Lack of validation of equipment /procedures in 
collection and processing facilities
• Inadequate audit activity e.g. 
− no SOP for audit,
− no written program for planned audits
− no documentation of results of audits 
− no formal process for disseminating results
•  Inadequate adverse event (AE) reporting/review-
ing. 
Centers often used a hospital-based incident report-
ing system, but in many cases it appeared from the num-
ber of reported AEs that this was not adequate to meet 
the needs of the HSCT program. Often it was not clear 
that all AEs were reviewed by the program director and/
or that a report was issued to the patient’s physician.
Other significant problems included those related to 
donor selection and testing, labelling and process con-
trol. The commonest problems as documented for the 
clinical program, collection and processing facilities are 
summarised in Table 1. A list of common deficiencies is 
available on the JACIE website.
Centers often have problems in designing JACIE-
compliant labels. This has been addressed by the 
International Cellular Therapy Coding and Labeling 
Advisory Group which has published terminology 
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and designed suitable labels for CTPs which are based 
on the ISBT 128 standard for stem cell component 
identification. An implementation plan has also been 
published by this group. Further information is avail-
able at http://iccbba.org/cellulartherapy_home.html. 
A Workshop of the EU Normalisation Committee 
(CEN) has agreed to recommend a modified version of 
the ISBT 128 system to the EU Directorate General 
for Public and Consumer Health (DG SANCO).
Current status of centers including time taken 
for correction /accreditation
Eighty-two centers have been awarded accreditation at 
least once. Of these, 58 are currently accredited includ-
ing 4 reaccreditations and 7 of the remaining 10 centers 
whose accreditation has expired have presented them-
selves for reaccreditation (of the remaining 3 centers, 
one center has ceased transplantation and the other two 
centers have not yet requested reaccreditation). These 
7 centers are among the 48 programs that are either 
awaiting reports, correcting deficiencies or who have 
presented evidence of corrections for assessment. One 
center abandoned the accreditation process but subse-
quently reapplied alongside a clinical unit. 
The time taken by centers to present documentary 
evidence of corrections of deficiencies in 2007 varied 
from 18 to 297 days with an average of 130 days. In 
general the maximum amount of time allowed to cor-
rect deficiencies is 9 months (from the time the center 
receives the Accreditation Committee’s report.) 
Experience of centers implementing JACIE
It was anticipated that implementation of the JACIE 
standards would pose some difficulties for applicant 
centers, particularly in relation to establishing a QM 
system and accompanying documentation. While QM 
is well established in laboratory practice, and most pro-
cessing facilities will already have an established QM 
program, QM programs were rarely in place in clinical 
units. It was also anticipated that there would be re-
source implications in terms of staff time because of the 
amount of detailed documentation that is required to 
demonstrate compliance with the standards. 
We undertook two surveys designed to assess the 
difficulties experienced by centers in preparing for ac-
creditation. The results of these surveys have been 
published in detail before.8 Briefly, in the first survey 
we found that, in most centers, at least 18 months was 
needed for preparation. Twenty-two centers had addi-
tional staff other than the Program Director to manage 
project implementation, but these staff were only part-
time in 13 centers and only 11 had any experience in 
quality management. The area of greatest difficulty for 
most centers was in the clinical program. Most difficul-
ty was found in implementing the QM system, adverse 
event reporting system and other documentation. Some 
centers already had written policies and SOPs, an audit 
system and an adverse event reporting system, but in all 
cases further development was needed to bring theses 
aspects of QM up to the required standard. 
The results of the survey were consistent with the 
findings of the inspectors that the most common defi-
ciencies were inadequacies in the QM system. Our find-
ings also indicated that these arise from lack of trained 
staff and absence of QM culture, particularly in the 
clinical setting. There is clearly an important need for 
training of clinical staff (doctors and nurses) in quality 
management. It is also important for centers to have a 
designated quality manager who has appropriate expe-
rience in quality management systems. 
In a second survey all responding centers indicated 
that they had benefited from implementing the JACIE 
standards. The areas of greatest perceived benefit were 
in procedure and practices, staff motivation, control 
of adverse events, and co-ordination between differ-
ent areas of the program. Significant benefits were also 
perceived in patient satisfaction, facilities, patient care 
and safety and training of new and existing staff. The 
areas where little or no benefit was noted were in costs, 
compliance with requirements of health insurers/social 
security and in government recognition. It was evident 
that implementation and maintenance of a quality sys-
tem increases the running costs of a program. Eighty-
one percent of the centers reported that implementation 
of the QM system had highlighted a need for changes 
in the implementation of the transplant program and all 
felt that accreditation was worth the effort invested 
Implications of the EU Directive 2004/23/EC 
and supporting Commission Directives
The requirements of Directive 2004/23/EC became 
law in EU member States on April 7th, 2006. The 
implementation of the parent Directive is supported 
by two Commission Directives (2006/17/EC and 
2006/86/EC) which set out the detailed technical re-
quirements. They cover (i) donation, procurement and 
testing, and (ii) coding, processing, preservation, storage 
and distribution and were published on February 8th 
2006 and 24th October 2006, respectively. The current 
JACIE standards conform to the requirements of the 
Directive as regards donation, procurement and pro-
cessing of stem cells, although JACIE is more detailed 
in many areas and JACIE standards also cover clinical 
transplant programs. However in some areas more ex-
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plicit wording of the JACIE standards is required to 
fulfil the requirements of the Directive and appropriate 
changes were incorporated into the 3rd and 4th editions 
of the FACT-JACIE standards. 
While support for accreditation among the profes-
sional transplant community is high, there are varying 
levels of engagement with JACIE by the regulatory au-
thorities in different countries. It has proven very difficult 
to build up a standard picture of official support across 
the EU due to significant differences in regulatory struc-
tures, varying readiness to implement the Directive and 
political issues. However, it can be said that in a number 
of countries there has been support from the regulatory 
authorities, both direct and indirect, for the JACIE ac-
creditation system. This is the case in Austria, Belgium, 
France, Italy, The Netherlands, and the United Kingdom. 
In Spain, the National Transplant Organization (ONT) 
has signed a formal agreement with JACIE and national 
scientific societies which gives official support to volun-
tary accreditation by transplant units and will recognise 
accredited programs as meeting quality and safety re-
quirements. (http://www.ont.es/contenido.jsp?id_nodo
=306&&&keyword=&auditoria=F) 
Outside the EU, a Swiss law on regulating trans-
plants enacted in July 2007 directly cites JACIE in re-
lation to HSC transplants and JACIE is cited as part 
of the law on compulsory health insurance requiring 
HSC centers to be certified by the Swiss Transplant 
Workgroup on Blood And Marrow Transplantation 
(STABMT) in accordance with JACIE Standards. All 
10 HSC centers in the country have undergone inspec-
tion and the majority are now accredited. 
Global harmonization of standards
JACIE, FACT, Netcord, AABB (formerly the American 
Association of Blood Banks) and the World Marrow 
Donor Association (WMDA) are working together to 
promote consistent interpretation of the requirements 
of the standards and guidance produced by each orga-
nization. A detailed comparison of the requirements of 
the EU Directives with the FACT-JACIE, Netcord-
FACT, AABB and WMDA standards in being un-
dertaken. It is a fundamental aim of JACIE to ensure 
that the FACT- JACIE standards as far as possible are 
harmonised with other applicable national and interna-
tional requirements, including those of the EU. This is 
particularly important to prevent difficulties in import-
ing and exporting tissues across international boundar-
ies, which could occur if there were to be differences in 
the standards adopted in different countries. 
One of the results of this collaborative approach 
has been the establishment of the Alliance for the 
Harmonisation of Cellular Therapy Accreditation 
(AHCTA)9 whose members include AABB, American 
Society for Blood & Marrow Transplantation 
(ASBMT); European Group for Blood & Marrow 
Transplantation (EBMT); Foundation for the 
Accreditation of Cellular Therapy (FACT); 
International NETCORD Foundation; International 
Society for Cellular Therapy (Europe) (ISCT); Joint 
Accreditation Committee ISCT-EBMT ( JACIE); and 
WMDA. AHCTA has developed a position paper on 
issues arising out of the import and export of HSC, to-
gether with a brief definition of the minimal standards 
that might be used to assess the provenance of imported 
HSC. The documents are accessible at www.ahcta.org. 
Within the EU discussions are now beginning on the 
establishment of a register of HSC collection centers 
and how this might be supported and hosted.
Conclusions
The FACT-JACIE accreditation system is now firmly 
established in Europe and the experience of centers 
that have been inspected is that implementation of the 
JACIE standards has led to significant improvements in 
different aspects of their transplant programs. JACIE 
has further assisted with a number of training courses 
for preparing centers for accreditation and has recent-
ly published a practical guide to quality management 
in transplant units. JACIE has also developed a close 
working relationship with other organizations involved 
in cellular therapy, which will form the basis for a new 
global approach to harmonisation of standards and ac-
creditation systems worldwide. This collaboration repre-
sents an innovative and proactive approach to solving the 
problems of international exchange of tissues and cells 
as these relate to the stem cell transplant community.
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